[HTML][HTML] Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional …
C McCabe, H Wright, K Polson, AJ Wagner - Orphanet Journal of Rare …, 2023 - Springer
Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
[HTML][HTML] Eco-Friendly, Simple, Fast, and Sensitive UPLC-MS/MS Method for Determination of Pexidartinib in Plasma and Its Application to Metabolic Stability
E Ezzeldin, M Iqbal, YA Asiri, GAE Mostafa, AYA Sayed - Molecules, 2022 - mdpi.com
Pexidartinib is the first drug approved by the US Food and Drug Administration specifically to
treat the rare joint tumor tenosynovial giant cell tumor. In the current study, a validated …
treat the rare joint tumor tenosynovial giant cell tumor. In the current study, a validated …
Exploring the Effect of Compound Glycyrrhizin and Silybinin on the Metabolism of Pexidartinib in Rats Based on CYP3A4 and CYP2C9
Y Su, X Wei, Q Cheng, H Qi, J Chen… - … in Pharmacological and …, 2023 - Wiley Online Library
Pexidartinib offered a new therapeutic option for adult patients with symptomatic
tenosynovial giant cell tumor (TGCT) who were refractory to surgical treatment and had …
tenosynovial giant cell tumor (TGCT) who were refractory to surgical treatment and had …
Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT
WD Tap, AS Singh, SP Anthony, M Sterba… - Clinical Cancer …, 2022 - AACR
Purpose: To assess the response to pexidartinib treatment in six cohorts of adult patients
with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor …
with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor …
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
R Wesolowski, N Sharma, L Reebel… - … in medical oncology, 2019 - journals.sagepub.com
Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of
pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with …
pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with …
Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib
PS Shankarappa, CJ Peer, A Odabas… - Cancer chemotherapy …, 2020 - Springer
Purpose Pexidartinib (PLX3397) is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
under clinical evaluation for potential CNS tumor treatment. This study aims to evaluate …
under clinical evaluation for potential CNS tumor treatment. This study aims to evaluate …
Disposition and mass balance of etrasimod in healthy subjects and in vitro determination of the enzymes responsible for Its oxidative metabolism
CA Lee, DA Oh, Y Tang, P Yi, M Bashir… - Clinical …, 2023 - Wiley Online Library
Etrasimod (APD334) is an investigational, once‐daily, oral, selective sphingosine 1‐
phosphate receptor 1, 4, 5 modulator (S1P1, 4, 5) in development for treatment of various …
phosphate receptor 1, 4, 5 modulator (S1P1, 4, 5) in development for treatment of various …
Effect of food on the pharmacokinetics of quizartinib
J Li, M Holmes, M Kankam, D Trone… - Clinical …, 2020 - Wiley Online Library
Quizartinib is an oral, highly potent, and selective type II FMS‐like tyrosine kinase 3 inhibitor
in development for acute myeloid leukemia. This parallel‐group study evaluated potential …
in development for acute myeloid leukemia. This parallel‐group study evaluated potential …
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines
M Scheffler, P Di Gion, O Doroshyenko, J Wolf… - Clinical …, 2011 - Springer
Abstract The 4-anilinoquinazolines (gefitinib, erlotinib and lapatinib) are members of a class
of potent and selective inhibitors of the human epidermal growth factor receptor (HER) family …
of potent and selective inhibitors of the human epidermal growth factor receptor (HER) family …
Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects
R Teng, M Kujacic, J Hsia - Clinical Therapeutics, 2014 - Elsevier
Purpose Ticagrelor is a reversibly binding P2Y 12 receptor antagonist used clinically for the
prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) …
prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) …